Kintara Therapeutics Inc KTRA shares are trading lower by 36% to $0.49 Wednesday afternoon and lower by 87% since Tuesday's open. The company has decided to stop developing their drug VAL-083 for glioblastoma because it didn't show better results than current treatments.
Kintara is now concentrating on REM-001, a localized tumor treatment, and looking into ways to enhance shareholder value through strategic options.
See Also: Why Sunrun (RUN) Stock Is Moving
What Else?
Preliminary study results for VAL-083 were disappointing, but the company says more data will be available in 2024 for further evaluation. They are planning to start a study for REM-001 in cutaneous metastatic breast cancer by the end of 2023, supported by a $2 million NIH grant.
Meanwhile, REM-001, a photodynamic therapy, has shown promise in previous trials, with an impressive 80% complete response rate in cutaneous metastatic breast cancer.
According to data from Benzinga Pro, KTRA has a 52-week high of $15.50 and a 52-week low of $0.48.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
